Silvercrest Asset Management Group LLC Trims Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Silvercrest Asset Management Group LLC lowered its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 535,255 shares of the biopharmaceutical company’s stock after selling 2,384 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Amicus Therapeutics were worth $5,042,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in FOLD. Park Avenue Securities LLC purchased a new stake in shares of Amicus Therapeutics in the 4th quarter worth approximately $123,000. Avanza Fonder AB purchased a new stake in shares of Amicus Therapeutics in the 4th quarter worth approximately $157,000. KBC Group NV grew its stake in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 3,120 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Amicus Therapeutics in the 4th quarter worth approximately $79,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Amicus Therapeutics by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company’s stock worth $597,000 after buying an additional 6,314 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on FOLD. Wells Fargo & Company cut their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. The Goldman Sachs Group cut their target price on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. UBS Group increased their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.22.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $6.43 on Monday. The business’s fifty day moving average price is $7.37 and its 200-day moving average price is $8.88. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -35.72, a PEG ratio of 1.51 and a beta of 0.64. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a 1-year low of $5.81 and a 1-year high of $12.65.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.